{
  "id": "c35c7aec-e8b1-4523-9bc5-a1a7fe1a2ff9",
  "title": "Vertex wins approval of new cystic fibrosis therapy Alyftrek",
  "link": "https://seekingalpha.com/news/4389495-vertex-wins-approval-of-new-cystic-fibrosis-therapy-alyftrek?utm_source=feed_news_all\u0026utm_medium=referral\u0026feed_item_type=news",
  "description": "",
  "author": "",
  "published": "Fri, 20 Dec 2024 18:04:29 -0500",
  "source": "https://seekingalpha.com/market_currents.xml",
  "categories": [
    "vrtx"
  ],
  "byline": "Jonathan Block",
  "length": 477,
  "excerpt": "Vertex Pharmaceuticals' Alyftrek has been approved as a new cystic fibrosis treatment taken once daily. Read more here.",
  "siteName": "Seeking Alpha",
  "favicon": "https://seekingalpha.com/samw/static/images/favicon-192x192.png",
  "text": "HealthcareCTRPhotos/iStock via Getty Images The U.S. FDA has approved Vertex Pharmaceuticals' (NASDAQ:VRTX) Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), a once-daily cystic fibrosis treatment. The drug is considered a next-in-class triple combination transmembrane conductance regulator (CFTR) modulator. It is approved for those six years and older who have at least one F508del mutation Recommended For YouAbout VRTX StockRelated StocksVRTX-Trending AnalysisTrending News",
  "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/499556881/image_499556881.jpg?io=getty-c-w750",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv id=\"content\"\u003e\u003carticle data-test-id=\"grid-container\"\u003e\u003cdiv\u003e\u003cdiv data-test-id=\"grid-col-main\"\u003e\u003cdiv data-test-id=\"card-container\"\u003e\u003cheader\u003e\u003cdiv data-test-id=\"quick-links\"\u003e\u003cul\u003e\u003cli\u003e\u003ca data-test-id=\"theme-links-item\" href=\"https://seekingalpha.com/market-news/healthcare#source=section%3Amain_content%7Csection_asset%3Athemes%7Cbutton%3Ahealthcare%7Cfirst_level_url%3Anews\"\u003e\u003cspan\u003e\u003cspan\u003eHealthcare\u003c/span\u003e\u003c/span\u003e\u003c/a\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/div\u003e\u003c/header\u003e\u003cdiv\u003e\u003cdiv data-test-id=\"content-container\"\u003e\u003cfigure data-type=\"getty-image\"\u003e\u003cpicture\u003e\u003cimg src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/499556881/image_499556881.jpg?io=getty-c-w750\" alt=\"Cystic Fibrosis\" data-id=\"499556881\" data-type=\"getty-image\" width=\"1536px\" height=\"1022px\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/499556881/image_499556881.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/499556881/image_499556881.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/499556881/image_499556881.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/499556881/image_499556881.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/499556881/image_499556881.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/499556881/image_499556881.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/499556881/image_499556881.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/499556881/image_499556881.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 768px) calc(100vw - 36px), (max-width: 1024px) calc(100vw - 132px), (max-width: 1200px) calc(66.6vw - 72px), 600px\"/\u003e\u003c/picture\u003e\u003cfigcaption data-type=\"getty-image\"\u003e\u003cp\u003eCTRPhotos/iStock via Getty Images\u003c/p\u003e\u003c/figcaption\u003e\u003c/figure\u003e\u003cul\u003e \u003cli\u003eThe U.S. FDA has approved Vertex Pharmaceuticals\u0026#39; (\u003cspan\u003eNASDAQ:\u003ca title=\"Vertex Pharmaceuticals Incorporated\" href=\"https://seekingalpha.com/symbol/VRTX\"\u003eVRTX\u003c/a\u003e\u003c/span\u003e) Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), a once-daily cystic fibrosis treatment.\u003c/li\u003e \u003cli\u003eThe drug is considered a next-in-class triple combination transmembrane conductance regulator (CFTR) modulator. It is approved for those six years and older who have at least one F508del mutation\u003c/li\u003e \u003c/ul\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"recommended-section\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch4 data-test-id=\"recommended-for-you-card-title\"\u003eRecommended For You\u003c/h4\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv data-test-id=\"post-skeleton\"\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"right-rail\"\u003e\u003cdiv data-test-id=\"about-symbol-card\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch3 data-test-id=\"about-symbol-card-title\"\u003eAbout VRTX Stock\u003c/h3\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv\u003e\u003cdiv data-test-id=\"about-symbol-chart\"\u003e\u003ctable data-test-id=\"table\"\u003e\u003cthead data-test-id=\"table-header\"\u003e\u003c/thead\u003e\u003ctbody data-test-id=\"table-body\"\u003e\u003c/tbody\u003e\u003c/table\u003e\u003cul\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"suggested-symbols-card\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch3 data-test-id=\"suggested-symbols-card-title\"\u003eRelated Stocks\u003c/h3\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv\u003e\u003ctable data-test-id=\"table\"\u003e\u003cthead data-test-id=\"table-header\"\u003e\u003c/thead\u003e\u003ctbody data-test-id=\"table-body\"\u003e\u003ctr\u003e\u003ctd\u003e\u003ca data-test-id=\"vrtx-link\" href=\"https://seekingalpha.com/symbol/VRTX#source=first_level_url%3Anews%7Csection%3Aright_rail%7Csection_asset%3Arelated_stocks%7Csymbol%3Avrtx%7Cline%3A1\"\u003eVRTX\u003c/a\u003e\u003c/td\u003e\u003ctd\u003e-\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/table\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"trending-articles-cards-container\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch2 data-test-id=\"trending-articles-cards-title\" id=\"trending-articles-cards-container\"\u003eTrending Analysis\u003c/h2\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv data-test-id=\"post-skeleton\"\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"trending-news-cards-container\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch2 data-test-id=\"trending-news-cards-title\" id=\"trending-news-cards-container\"\u003eTrending News\u003c/h2\u003e\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003c/article\u003e\u003c/div\u003e\u003c/div\u003e",
  "readingTime": "Less than 1 min",
  "publishedTime": "2024-12-20T23:04:29Z",
  "modifiedTime": "2024-12-20T18:04:51-05:00"
}
